And next year, Retatrutide is expected to enter the market, and this will work on 3 receptor sites, GLP-1, GIP and glucagon
In the ATTAIN-MAINTAIN trial, orforglipron's profile was "consistent with previous orforglipron Phase 3 studies." The most common adverse events were gastrointestinal-related and were generally mild-to-moderate in severity, which is expected for the GLP-1 class
For researchers transitioning from semaglutide or tirzepatide to retatrutide, the dose schedule requires a fresh start
To navigate this safely, its crucial to work closely with a healthcare provider who can help transition off GLP-1 medications and explore other options, like metformin or lifestyle adjustments
The pharmacy visit becomes an incidental part of the trip rather than the sole purpose, which makes the economics work regardless of distance
Some of the most common reasons include: Cost: GLP-1 drugs can run over $1,300 a month, and theyre not always covered by insurance